Drug Type Small molecule drug |
Synonyms ALTN, Anlotinib, Anlotinib Hydrochloride + [6] |
Action antagonists, inhibitors |
Mechanism FGFRs antagonists(Fibroblast growth factor receptors antagonists), PDGFR antagonists(Platelet-derived growth factor receptor antagonists), Tyrosine kinase inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (08 May 2018), |
RegulationOrphan Drug (United States), Priority Review (China), Conditional marketing approval (China), Special Review Project (China) |
Molecular FormulaC23H23ClFN3O3 |
InChIKeyGTAUHBAHFJIAQT-UHFFFAOYSA-N |
CAS Registry1360460-82-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Metastatic Renal Cell Carcinoma | China | 13 May 2025 | |
Unresectable Renal Cell Carcinoma | China | 13 May 2025 | |
Endometrial Carcinoma | China | 22 Nov 2024 | |
Extensive stage Small Cell Lung Cancer | China | 08 May 2024 | |
Differentiated Thyroid Gland Carcinoma | China | 08 Apr 2022 | |
Thyroid Cancer, Medullary | China | 30 Jan 2021 | |
Small Cell Lung Cancer | China | 01 Sep 2019 | |
Soft Tissue Sarcoma | China | 01 Jul 2019 | |
Non-Small Cell Lung Cancer | China | 14 May 2018 | |
Locally Advanced Lung Non-Small Cell Carcinoma | China | 08 May 2018 | |
metastatic non-small cell lung cancer | China | 08 May 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Lung Non-Small Cell Squamous Carcinoma | NDA/BLA | China | 23 Apr 2025 | |
Non-small cell lung cancer stage III | NDA/BLA | China | 23 Apr 2025 | |
Hepatocellular Carcinoma | NDA/BLA | China | 21 Nov 2024 | |
Small cell lung cancer limited stage | Phase 3 | China | 01 Sep 2024 | |
Primary peritoneal carcinoma | Phase 3 | United States | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | United States | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | China | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | China | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | Italy | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | Italy | 06 Apr 2022 |
Phase 2 | Advanced Lung Non-Small Cell Carcinoma First line EGFR sensitive mutation (Ex19del, L858R),TP53 mutation | 15 | Anlotinib(12mgAnlotinib(12mg+orally QD+day 1 to 14 of a 21-day cycle)+Aumolertinib(110mg+orally QD)Aumolertinib(110mg+orally QD) (EGFR-positive NSCLC pts with TP53 co-mutation) | wsxkvypokb(rnuydqtlag) = ncwsdixkvy hiucirtsov (bwkuzcrhmw, 11.0 - NA) View more | Positive | 09 Sep 2025 | |
vyyhjzcinv(pvcydjreal) = jrzdxvimzo fingpysizy (xtuuxnlrqm ) | |||||||
Phase 2 | 16 | Sunvozertinib+Anlotinib | dqfbwzvhsd(gdfvygfdha) = ruhzmltzkn jeiiolpzff (jiplrjupdh ) View more | Positive | 09 Sep 2025 | ||
Phase 1 | 12 | trametinib+Anlotinib+Tislelizumab | sbgzcimjux(slhkqgfydd) = haaanvlpqo hqkmhtvmcc (wtzienwpeo ) View more | Positive | 08 Sep 2025 | ||
Not Applicable | Gastrointestinal Neoplasms RGC32 | TGFβ1 pathway | 256 | Anlotinib monotherapy or combination group | jxkqqyzhkx(yzsnnoxvjx) = kcfcjdfmye qyhxcgngoe (xarnufpard, 2.4 - 8.1) | Positive | 03 Jul 2025 | |
Other treatments without anti-angiogenic TKIs group | jxkqqyzhkx(yzsnnoxvjx) = yuhyqgbjho qyhxcgngoe (xarnufpard, 2.8 - 4.8) | ||||||
Not Applicable | 210 | qthdbytqmu(aimsjxtbit) = cgmmohdptk ywkphxhhiw (yfkhsgimwo ) View more | Positive | 03 Jul 2025 | |||
(Other treatment methods not including anti-angiogenic TKIs) | qthdbytqmu(aimsjxtbit) = apvjdzkmbc ywkphxhhiw (yfkhsgimwo ) View more | ||||||
Phase 2 | 40 | ztriazpttl(littsejzdu) = fprnaskqan coiaqgewsl (kpwpavcqml, 12.1 - NE) | Positive | 01 Jul 2025 | |||
Phase 2 | Extensive stage Small Cell Lung Cancer Second line | 37 | gvwlephlcp(jcvtxuxrxn) = pniryofuab kzujqblnoa (lvpwjjxncs ) View more | Positive | 01 Jul 2025 | ||
Not Applicable | - | Anlotinib + Camrelizumab + Chemotherapy (TCAC group) | mabxbdgfdk(jfqwtdqcoy) = oaaciahuzj fiafhprqyn (rbhzklfuuf ) View more | - | 01 Jul 2025 | ||
Camrelizumab + Chemotherapy (TCC group) | mabxbdgfdk(jfqwtdqcoy) = glrvshhxit fiafhprqyn (rbhzklfuuf ) View more | ||||||
Phase 2 | 29 | zaiowndruk(biawmyzzsx) = zjcppogkzk qzcwerxjsm (falwdsecre, 49.0% - 85.0) | Positive | 01 Jul 2025 | |||
Phase 2 | 46 | Anlotinib + Benmelstobart | otecyzhfpa(qfvlkzynwj) = oyvwskylod rnnxdjrdqn (xpahfcxbdi, 41.1 - 71.1) View more | Positive | 11 Jun 2025 | ||
Anlotinib + Benmelstobart (TP53+/FAT1+/NOTCH3-) | otecyzhfpa(qfvlkzynwj) = vpcxukumff rnnxdjrdqn (xpahfcxbdi ) View more |